Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Reich, O; Regauer, S; Kashofer, K.
Possibly carcinogenic HPV subtypes are a cause of HSIL and negative clinical HPV tests - A European prospective single center study.
Gynecol Oncol. 2020; 158(1):112-116 Doi: 10.1016/j.ygyno.2020.04.685
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Reich Olaf
Co-authors Med Uni Graz: Kashofer Karl; Regauer Sigrid
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: To correlate p16^ink4a positive cervical precancers of 388 consecutive patients from a single European center with the preceding clinical HPV-DNA and HPV E6/E7 mRNA screening test. 374/388 patients had a HSIL (CIN 2/3) and 14/388 AIS (6 pure and 8 combined AIS/HSIL). Lesional tissues of HSIL/AIS with negative Cobas and/or Aptima HPV tests underwent HPV genotyping with CHIPRON HPV 3.5 LCD-array. Selected cases were subjected to a cancer hot spot analysis. The Aptima test missed 10/388 (2.6%) and the Cobas test seven of 388 (1.8%) precancers associated HPV-HR. Both HPV tests were negative in 20/374 precancers (5.3%; 17 HSIL/CIN3, two HSIL/CIN2, one AIS). Due to insufficient DNA four of 20 double negative cases (three HSIL, one AIS) were not genotyped. In the remaining cases, two of 20 (10%) HSIL genotyping detected HR-HPV subtypes. 10/20 (50%) HSIL were associated with possibly carcinogenic and low risk HPV (four x HPV73, three x HPV 53, one x HPV 82, one x HPV 67 and one x HPV 6), all of which are not included in both HPV tests. Two of 20 (10%) HSIL were negative with all HPV tests; one of these HSIL had a somatic PIK3CA gene mutation and the other had a single nucleotide variant in the APC gene. Three of 20 HSIL (15%) were thin HSIL (≤9 cell layers thick). Possibly carcinogenic HPV subtypes not included in the clinical HPV tests may account for the small gap of missed HSIL in clinical HPV screening. True HPV negative HSIL are exceedingly rare. Expanding HPV testing to include more possibly carcinogenic HPV subtypes may further reduce cervical cancer. Copyright © 2020 Elsevier Inc. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing): Adult -; Cervical Intraepithelial Neoplasia - epidemiology; Cervical Intraepithelial Neoplasia - pathology; Cervical Intraepithelial Neoplasia - virology; Cyclin-Dependent Kinase Inhibitor p16 -; DNA, Viral - analysis; DNA, Viral - genetics; DNA, Viral - epidemiology; Female -; Humans -; Middle Aged -; Papillomaviridae - genetics; Papillomaviridae - isolation & purification; Papillomavirus Infections - epidemiology; Papillomavirus Infections - pathology; Papillomavirus Infections - virology; Prospective Studies -; RNA, Messenger - analysis; RNA, Messenger - genetics; RNA, Viral - analysis; RNA, Viral - genetics; Squamous Intraepithelial Lesions - epidemiology; Squamous Intraepithelial Lesions - genetics; Squamous Intraepithelial Lesions - pathology; Squamous Intraepithelial Lesions - virology; Uterine Cervical Neoplasms - epidemiology; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - virology; Young Adult -
Find related publications in this database (Keywords): Cervical cancer screening; HPV genotype; Cervical intraepithelial lesion; Adenocarcinoma in situ; HPV-DNA testing; HPV-E6/E7 mRNA testing; Possibly carcinogenic; Probably carcinogenic HPV; Athena trial